Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ: ETON )

15.73 +0.25 (+1.61%)
Streaming Delayed Price Updated: 3:13 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 98,181
Open 15.47
Bid (Size) 15.72 (1)
Ask (Size) 15.76 (3)
Prev. Close 15.48
Today's Range 15.25 - 16.03
52wk Range 3.110 - 18.41
Shares Outstanding 25,688,062
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S. 
From Eton Pharmaceuticals
Via GlobeNewswire
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know
Via Benzinga

Performance

YTD
+9.92%
+9.92%
1 Month
+6.36%
+6.36%
3 Month
+7.30%
+7.30%
6 Month
+93.48%
+93.48%
1 Year
+379.57%
+379.57%

More News

Read More
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For March 18, 2025
Via Benzinga
The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts
Via Benzinga
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Analyst Expectations For Eton Pharmaceuticals's Future
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For Eton Pharmaceuticals
Via Benzinga
Critical Insights From Eton Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
From Eton Pharmaceuticals
Via GlobeNewswire
SWK Holdings Provides Portfolio Update
Via ACCESSWIRE
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.